KelsenD.: Adjuvant and neoadjuvant therapy for gastric cancer.Semin Oncol, 23: 379–389, 1996.
6.
WilkeH., PreusserP., FinkU, ArchterrathW., MeyerH.J., StahlM., LenazL., MeyerJ., SiewartJ.R., GeerlingsH.: New developments in the treatment of gastric carcinoma.Semin Oncol, 17: 61–70, 1990.
7.
RosenH.R., ScheithauerW., JakeszR.: Epirubicin, etoposide and cisplatin in the treatment of locally advanced nonresectable gastric carcinoma-results of a multicentric pilot study.GI Cancer, 1: 49–53, 1995.
8.
PlukkerJ., MulderN.H., SleijferD.T., GrandJ., VerschuerenR.C.: Chemotherapy and surgery for locally advanced cancer of the cardia and fundus: phase II study with methotrexate and 5fluorouracil.Br J Surg, 7: 1318–1326, 1991.
9.
SchuhmacherC.P., FinkU., BeckerK., BuschR., DittlerH.J., MuellerJ., SiewertJ.R.: Neoadjuvant therapy for patients with locally advanced gastric carcinoma with etoposide, doxorubicin, and cisplatinum. Closing results after 5 years of follow-up.Cancer, 91: 918–927, 2001.
10.
MelcherA.A., MortD., MaughanT.S.: Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.Br J Cancer, 74: 1651–1654, 1996.
11.
CascinuS., LabiancaR., GrazianoF., PanceraG., BarniS., FrontiniL., LuporiniG., CellerinoR., CatalanoG.: Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).Br J Cancer, 78: 390–393, 1998.
12.
CascinuS., GrazianoF., Del FerroE., StaccioliM.P., LigiM., CarnevaliA., MurettoP., CatalanoG.: Expression of p53 protein and resistance to preoperative chemotherapy in locally advanced gastric carcinoma.Cancer, 83: 1917–1922, 1998.
13.
BokuN., ChinK., HosokawaK., OhtsuA., TajiriH., YoshidaS., YamaoT., KondoH., ShiraoK., ShimadaY., SaitoD., HasebeT.: Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5fluorouracil and cisplatinum.Clin Cancer Res, 4: 1469–1474, 1998.
14.
ShimadaK., AjaniJ.A.: Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials.Cancer, 86: 1657–1668, 1999.
15.
HermansJ., BonenkampJ.J., BoonM.C., BuntA.M., OhyamaS., SasakoM., Van de VeldeC.J.: Adjuvant therapy after curative resection for gastric cancer: meta-analysis of randomized trials.J Clin Oncol, 11: 1441–1447, 1993.
16.
PignonJ.P., DucreuxM., RougierP.: Meta-analysis of adjuvant chemotherapy in gastric cancer: a critical reappraisal.J Clin Oncol, 12: 877–878, 1994.
17.
EarleC.C., MarounJ.A.: Adjuvant chemotherapy after curative resection for gastric cancer in non Asian patients: revisiting a meta-analysis of randomized trials.Eur J Cancer, 35: 1059–1069, 1999.
18.
MariE., FlorianiI., TinazziA., BudaA., BelfiglioM., ValentiniM., CascinuS., BarniS., LabiancaR., TorriV.: Efficacy of adjuvant chemotherapy after curative resection for gastric cancer: a meta-analysis of published randomized trials.Ann Oncol, 11: 837–843, 2000.
19.
MacdonaldJ.S., SmalleyS.R., BenedettiJ., HundahlS.A., EstesN.C., StemmermannG.N., HallerD.G., AjaniJ.A., GundersonL.L., JessupJ.M., MartensonJ.A.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction.N Engl J Med, 345: 725–730, 2001.
20.
SchipperD.L., WagenerD.J.T.: Chemotherapy of gastric cancer.Anticancer Drugs, 7: 137–149, 1996.
21.
CascinuS.: Nuovi orientamenti nel trattamento chemioterapico del carcinoma gastrico.Tumori, 85: A1–A5, 1999.
22.
VanhoeferU., RougierP., WilkeH., DucreuxM.P., LacaveA.J., Van CutsemE., PlankerM., SantosJ.G., PiedboisP., PaillotB., BodensteinH., SchmollH.J., BleiborgH., NordlingerB., CouvreurM.L., BaronB., WilsJA.Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group.J Clin Oncol, 18: 2648–2657, 2000.
23.
SulkesA., SmythJ., SessaC., DirixL.Y., VermorkenJ.B., KayeS., WandersJ., FranklinH., LeBailN., VerweijJ.: Docetaxel in advanced gastric cancer: results of a phase II clinical trial.Br J Cancer, 70: 380–383, 1994.
24.
ArtruP., AndrèT., TigaudJ., DouillardJ., GamelinE., BrunetR., RougierP., FrancoisE., JacobJ., LevoirD., YatagheneY., TaammaK., LouvetC.: Oxaliplatin and 5FU and folinic acid in advanced/metastatic gastric carcinoma patients: final results.Proc Am Soc Clin Oncol, 20: 654, 2001.
25.
SchneiderB.G., BravoJ.C., RoaJ.C., RoaI., KimM.C., LeeK.M., PlaisanceK.T.Jr., McBrideC.M., MeraR.: Microsatellite instability, prognosis and metastasis in gastric cancers from a low-risk population.Int J Cancer, 89: 444–452, 2000.
